Anti-PDL1 Immunotherapy Demonstrates Efficacy in Phase 2 NSCLC StudyLea EslavaKimPharmD
Fast drugs sensitivity assay To determine the combination of THZ1 and LY2228820 in patient-derived tumor cells, PDX tumors were digested with tissue dissociation buffer (0.1% collage- nase, 0.01% hyaluronidase, 0.01% DNase I in Hank's Bal- anced Salt Solution) for 1 h at room temperature (...
Initially, we used The Cancer Genome Atlas (TCGA) database to analyze the gene mutations of patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), respectively. We found that the high mutation rates of KEAP1 ranked in both LUAD and LUSC (FigureS1A, B). To inve...
Effect of YIV-906 and/or Anti-PD1 on PD1/PDL1 protein expression and T cell activity. (A) Effect of YIV-906 and/or Anti-PD1 on activated T cell of Hepa 1–6 tumor as indicated by Granyzme B and CD3 staining. (B) Effect of YIV-906 and/or Anti-PD1 on Treg cell of Hepa 1–...
with PD-1/PD-L1 blockers and the drugs were ranked based on their mechanism of action and known clinical efficacy. Nineteen drugs or drug classes were identified from an internal list of lead molecules and were scored for their clinical potential. Efficacy and safety data from pivotal studies ...
neutrophils, macrophages and NK cells), as well as adaptive immune cells, particularly T-lymphocytes in the TME (Table 1, Table 2). Table 1. List of clinical studies evaluated the effects of Se on antitumour immunity. Cancer TypeCohortSe baseline (normal: 40_150 μg L−1)Effects on ...
Additionally, DeMAND analysis identified IκBα as a leading potential target of NQBS-related compounds as determined from the unique gene signature generated from lymphoma cells exposed to the drugs. Finally, NQBS-related compounds potently inhibited lymphoma growth without significant toxicities observed...
Gura, et al., “Systems for Identifying New Drugs Are Often Faulty”. Science (Nov. 7, 1997); 278(5340): 1041-1042. Hamid, O. et al., “Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma,” New England Journal of Medicine (2013); 369(2): 134-144. Hofmeye...
The antibodies of the present invention may be combined synergistically with one or more anti-cancer drugs or therapy used to treat cancer, including, for example, renal cell carcinoma, colorectal cancer, glioblastoma multiforme, squamous cell carcinoma of head and neck, non-small-cell lung cancer...
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysisXIAN, F.WU, J.YUAN, Y.-L.BIE, J.XU, G.-H.European Review for Medical & Pharmacological Sciences...